A venture capital firm with multiple offices in the USA has assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Invests Exclusively in Mental Health and Neurology, Interested in All Sectors of Life Sciences From Therapeutics to Digital Health
A venture capital firm based out of USA that invests exclusively in the mental health and neurology space. The firm’s biotech segment is interested in companies related to neuroscience and neurotherapeutics. The firm is raising their second fund right now, their first fund closed at over $22M. The firm looks to make Seed and Series A investments in the form of equity or convertible notes with a typical check size ranging from $500K-1.5M. The firm seeks to make investments in North America and Europe.
The firm is open to all 4 sectors as they relate to neurology. The firm is agnostic to subsector and indication with a particular focus on psychiatry and neurodegenerative diseases. The firm is open to pre-clinical and pre-prototype companies and is open to all 3 classes of medical devices with a stronger focus on 510K and PMA.
The firm is open to all types of management teams and is willing to lead or co-invest and will seek a board seat when leading.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
The Power of Your Pitch
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
If capital launches the early-stage life science startup into space, then pitching is the match that lights the rocket. If only the process were as straightforward as lighting a simple match. Each step of an early-stage startup’s life takes careful planning, research, and strategy, and while Life Science Nation (LSN) has many resources to help them be successful, one of the most powerful are the tools designed to help them pitch directly to investors who are a fit for their product and stage of development.
Today’s free webinar, Maximizing the Power of Your Pitch will walk attendees through, not only the process of the RESI Boston Innovator’s Pitch Challenge (IPC), but also tried-and-true tools to help founders pitch powerfully. Not all pitches are created equal, and every audience may have different feedback, but over the past decade, LSN has seen trends come and go and has developed systems around what works. Join us at 2 PM EDT to learn more about pitching at RESI, fielding questions, and delivering a pitch that communicates your story well.
Interested in joining the IPC? Sign up by July 29 and save $300 on early bird rates! Applications are accepted on a rolling basis, so get yours in today!
Exhibit at RESI Boston
By Candice He, Vice President of Business Development, Global Investment Strategist, LSN
RESI returns to Boston for its first in-person conference in over two years September 21-22, with an additional day of virtual partnering on September 23. Past in-person RESIs boasted a vibrant network of service providers, including CRO/CMOs, non-profits, suppliers, and professional services like law firms and banks. These service providers have played an essential role in the RESI ecosystem, and we are pleased to welcome them back with more offerings that include both onsite and digital formats to promote their services and connect them with early-stage startups who need them.
RESI’s unique value to its service providers is its dedication to early-stage companies in life science and healthcare. These startups have specific needs that make them ideal clients for a variety of providers. CRO/CMOs attend RESI to connect with preclinical therapeutics. Lab services with valuable R&D space, banks with life science-specific benefits, and law firms specializing in IP, term sheet negotiations, and more exhibit at RESI to connect with these founders who seek their services.
RESI exhibition includes a table for promotion and networking in the exhibit hall, as well as a dedicated webpage for additional marketing materials and connections with virtual attendees. Exhibitors also have their logo featured prominently on the RESI website, live agenda, program guide, and onsite signage. For $4K, the exhibitor package also includes a complimentary registration to participate in the partnering platform and attend all conference events. Interested in reaching a broad audience of early-stage entrepreneurs at RESI Boston? Check out our sponsorship brochure and contact us to learn more!
|
Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
 |
 |
 |
 |
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Alexander Vassallo
Manager of Business Development, Entrepreneurial Education Lead Book a Meeting Email Me |
Summer of Savings Continues
By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN
The summer of savings continues with RESI Boston’s early bird rates available until July 29. RESI returns to Boston September 21-22, with an additional day of dedicated virtual partnering September 23. RESI attracts early-stage founders and CEOs of life science and healthcare startups seeking capital and licensing partners. These attendees are actively seeking funding, therefore, creating a valuable experience at an affordable rate is essential to their enthusiastic participation in RESI’s vibrant partnering and networking format.
Startups can save $300 with early bird rates when they register by July 29. Additionally, free webinars to enhance partnering and pitching, as well as how to make the most of the RESI experience are available throughout the summer. Sign up for a free webinar below and register for RESI Boston today and save!
July 7 | 2 PM EDT – Maximizing the Power of Your Pitch
Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.
July 13 | 12 PM EDT – Fundraising Bootcamp: It All Starts with the Story
The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.
July 20 | 1 PM EDT – Supporting Tech Hub Startups at RESI
This workshop is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startup constituents who’ve raised less than $2M expand outreach from Regional to Global, build a target list of investors, and more.
July 26 | 11 AM EDT – Fundraising Bootcamp: Branding Your Company from Seed to Series B
Many companies have great science and a compelling project to tell investors about, but don’t have the right tools to communicate effectively. What are the elements of marketing collateral needed to efficiently fundraise in the early stages? This webinar will dive into this important subject and help you to build a powerful marketing collateral for your fundraise.
August 3 | 11 AM EDT – Maximizing the Power of Your Pitch
Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.
August 17 | 1 PM EDT – Keys to Successful Partnering
Partnering events like the RESI conference series are a fundamental part of fundraising. They present a great opportunity to meet new potential investors and strategic partners but getting the meetings you want is competitive and difficult. What strategies have proven successful to get the most meetings? What can you do to stand out and have a better chance of catching the attention of investors? This webinar will address these and other important aspects of partnering.
Hot Investor Mandate: Large Healthcare Company Invests Up to $10M in North America or China-Based Life Science Companies in Oncology, CNS, Women’s Health, and More
A fully integrated healthcare solution provider headquartered in China is leading in several market segments in Asia, including family planning medicines, anesthesia, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.
The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.
The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Strategic Corporate VC Fund Invests in Early-Stage Therapeutics and Drug Discovery Technologies With Strongest Interest in Oncology
A strategic corporate venture capital fund of an oncology pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities mainly in USA and Europe.
The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the corporate’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.
While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.
The firm is looking for teams with strong sector expertise. With the support of the corporate’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 